johndunneclimbing.com
John Dunne Climbing – About
http://johndunneclimbing.com/about
John started climbing at the age of 10 on the local cliffs close to his home in Bradford West Yorkshire. He then went on to establish a series of World class new routes including the first route to be graded 8b in Britain, Magnetic Fields at Malham Cove and the hardest route on gritstone at the time, New Statesman E8, 7a at Ilkley Yorkshire in 1987. In 1987 John competed internationally placing 2. At the Troubat World cup in France.
johndunneclimbing.com
John Dunne Climbing – Business
http://johndunneclimbing.com/business
John Dunne Chief Executive Officer Climbing Centre Group. Web: Climbing Centres’ Website.
sparkimpact.co.uk
Zilico Ltd | Spark Impact
http://sparkimpact.co.uk/partner-view/zilico-ltd
News & Events. Http:/ www.zilico.co.uk. Zilico Ltd is pioneering new technologies that will allow swifter, more accurate detection of cervical cancer and pre-cancerous conditions. E: info@sparkimpact.co.uk. Liverpool Science Park,. 131 Mount Pleasant,. Companies House Number 02323420. 50 Athol Street,. Douglas, Isle of Man. Managed and maintained by PixelStone.net. SPARK Impact Limited is authorised and regulated by the Financial Conduct Authority FRN 143361. News & Events.
sparkimpact.co.uk
Cytox and Affymetrix form strategic partnership | Spark Impact
http://sparkimpact.co.uk/cytox-and-affymetrix-form-strategic-partnership-to-develop-and-commercialize-blood-based-genetic-assay-for-alzheimers-disease-risk-assessment
News & Events. Cytox and Affymetrix form strategic partnership. July 17, 2015. An innovative developer of assays for risk assessment and prediction of dementia, and Affymetrix. Nasdaq:AFFX), a leading provider of translational research and diagnostic solutions, announce a strategic partnership. The two companies are to collaborate on developing and commercializing a blood-based genetic assay for research in diagnosis and prognosis of Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI). Companies...
sparkimpact.co.uk
About Us | Spark Impact
http://sparkimpact.co.uk/about
News & Events. SPARK Impact is one of the most active investors in the UK. Our extensive knowledge and experience adds value to entrepreneurs and investors:. We seek to build world-class businesses that offer best investment return. We support businesses from across a wide range of industry sectors. We work with early stage, rapid growth and mature businesses seeking significant growth and expansion. Support for entrepreneurs, at the time they need it and in ways that enable them to flourish. Investment ...
sparkimpact.co.uk
News & Events | Spark Impact
http://sparkimpact.co.uk/news-events
News & Events. Cytox presentations on studies with breakthrough genetic biomarker research assay for Alzheimer’s disease risk assessment at CTAD 2016. December 1, 2016. Novel SNP profiling approach for AD risk stratification to be highlighted in San Diego 1st December 2016, Oxford, UK. Cytox Ltd, an innovative…. November 28, 2016. November 28, 2016 Perfectus Biomed are delighted to formally announce that the company has been awarded the Technical Service Award by Bionow at…. November 7, 2016. Cytox early...
sparkimpact.co.uk
Absynth appears in industry report | Spark Impact
http://sparkimpact.co.uk/absynth-appears-in-industry-report
News & Events. Absynth appears in industry report. August 10, 2015. Our investee company Absynth Biologics. Is one of the companies featured in a new report published by the UK BioIndustry Association (BIA). Published following the announcement of the last round of the current Biomedical Catalyst (BMC). Funding allocation, the report ‘The Biomedical Catalyst’ gives a retrospective of the current scheme and showcases ten case studies from companies who have been recipients of BMC funding. 50 Athol Street,.
sparkimpact.co.uk
Funds | Spark Impact
http://sparkimpact.co.uk/funds
News & Events. SPARK Impact is a multi-fund manager located in the UK and authorised and regulated by the Financial Conduct Authority. The firm is authorised to undertake portfolio fund management as well as being authorised as a Small authorised Sub Threshold Alternative Investment fund manager. Our role is to identify suitable investment opportunities, conduct due diligence, negotiate, structure investment transactions, and monitor and manage investments until exit. The scheme will provide support to s...
